Ferumoxytol
- Generic Name
- Ferumoxytol
- Brand Names
- Feraheme
- Drug Type
- Small Molecule
- Chemical Formula
- Fe3O4
- CAS Number
- 722492-56-0
- Unique Ingredient Identifier
- G6N3J05W84
- Background
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
...
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) .
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 121
- Registration Number
- NCT02791568
- Locations
- ๐บ๐ธ
UnityPoint Health-Meriter Hospital, Madison, Wisconsin, United States
๐บ๐ธUniversity of Wisconsin-Hospitals and Clinics, Madison, Wisconsin, United States
Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Paul Finn
- Target Recruit Count
- 17
- Registration Number
- NCT02752191
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 2014
- Registration Number
- NCT02694978
- Locations
- ๐ต๐ท
Clinical Trial Site, Ponce, Puerto Rico
๐บ๐ธAMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT02689401
Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Beau Nakamoto
- Target Recruit Count
- 30
- Registration Number
- NCT02678767
- Locations
- ๐บ๐ธ
Hawaii Center for AIDS, Honolulu, Hawaii, United States
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT02631733
- Locations
- ๐บ๐ธ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
๐บ๐ธNCI - Center for Cancer Research, Bethesda, Maryland, United States
๐บ๐ธNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 34
- Registration Number
- NCT02549898
- Locations
- ๐ฉ๐ฐ
Rigshospitalet Glostrup, Glostrup, Denmark
In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 14
- Registration Number
- NCT02511028
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Michael Iv
- Target Recruit Count
- 10
- Registration Number
- NCT02452216
- Locations
- ๐บ๐ธ
Stanford University Hospitals and Clinics, Stanford, California, United States
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT02359097
- Locations
- ๐บ๐ธ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.